Natalizumab
- Generic Name
- Natalizumab
- Brand Names
- Tysabri, Tyruko
- Drug Type
- Biotech
- Chemical Formula
- -
- CAS Number
- 189261-10-7
- Unique Ingredient Identifier
- 3JB47N2Q2P
- Background
Natalizumab is a recombinant humanized IgG4κ monoclonal antibody that binds to α4-integrin. While natalizumab was originally approved by the FDA to treat multiple sclerosis in 2004, it was withdrawn from the market following multiple reports of fatal progressive multifocal leukoencephalopathy (PML). In 2006, the FDA reintroduced the drug to the market for mu...
- Indication
Natalizumab is indicated as monotherapy for the treatment of relapsing forms of multiple sclerosis, including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease in adults.
...
- Associated Conditions
- Relapsing Remitting Multiple Sclerosis (RRMS), Secondary Progressive Multiple Sclerosis (SPMS), Severe Crohn's Disease, Moderate Crohn’s Disease
- Associated Therapies
- -
Examining the Risk of Skin Cancer in Multiple Sclerosis Patients Using Fingolimod: a Population-Based Study
- First Posted Date
- 2024-11-26
- Last Posted Date
- 2024-11-26
- Lead Sponsor
- University of British Columbia
- Target Recruit Count
- 4000
- Registration Number
- NCT06705608
A Study Utilising Data From European Union (EU) National Multiple Sclerosis (MS) Registries to Assess the Incidence of Anti-Natalizumab Antibody Among Participants Who Receive Subcutaneous Administration of Natalizumab for Treatment of Relapsing-remitting Multiple Sclerosis (RRMS)
- First Posted Date
- 2023-06-29
- Last Posted Date
- 2024-08-23
- Lead Sponsor
- Biogen
- Target Recruit Count
- 400
- Registration Number
- NCT05925049
- Locations
- 🇺🇸
Research Site, Cambridge, Massachusetts, United States
A Study of End of Dose Phenomena in Subcutaneous Natalizumab Treated Multiple Sclerosis (MS) Participants
- First Posted Date
- 2023-01-27
- Last Posted Date
- 2024-06-14
- Lead Sponsor
- Biogen
- Target Recruit Count
- 34
- Registration Number
- NCT05701423
- Locations
- 🇩🇪
Klinik für Neurologie, Universitätsklinikum Düsseldorf, Düsseldorf, Germany
Motixafortide and Natalizumab to Mobilize CD34+ Hematopoietic Stem Cells for Gene Therapies in Sickle Cell Disease (SCD)
- Conditions
- Interventions
- First Posted Date
- 2022-11-16
- Last Posted Date
- 2024-10-07
- Lead Sponsor
- Washington University School of Medicine
- Target Recruit Count
- 10
- Registration Number
- NCT05618301
- Locations
- 🇺🇸
Washington University School of Medicine, Saint Louis, Missouri, United States
A Study to Investigate the Radiological Onset of Action After Treatment Initiation With Subcutaneous (SC) Natalizumab in Participants With Relapsing-Remitting Multiple Sclerosis (RRMS)
- First Posted Date
- 2022-09-08
- Last Posted Date
- 2024-06-21
- Lead Sponsor
- Biogen
- Target Recruit Count
- 1
- Registration Number
- NCT05532163
- Locations
- 🇩🇪
Neurologische Studiengesellschaft Bonn GbR, Bonn, Germany
🇩🇪Neurologische Praxis Dr. med. Boris-Alexander Kallmann, Bamberg, Germany
A Study for Tysabri Participant Preference
- First Posted Date
- 2022-03-31
- Last Posted Date
- 2024-05-17
- Lead Sponsor
- Biogen
- Target Recruit Count
- 318
- Registration Number
- NCT05304520
- Locations
- 🇩🇪
Katholisches Klinikum Bochum gGmbH, Bochum, Germany
🇩🇪Neurologie am Mexikoplatz, Berlin, Germany
🇩🇪Neurologie Neu-Ulm, Neu-Ulm, Germany
A Study to Evaluate Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of Multiple Doses of Natalizumab (BG00002) Administered Subcutaneously to Japanese Participants With Relapsing-Remitting Multiple Sclerosis
- First Posted Date
- 2022-03-03
- Last Posted Date
- 2024-07-05
- Lead Sponsor
- Biogen
- Target Recruit Count
- 21
- Registration Number
- NCT05265728
- Locations
- 🇯🇵
National Center of Neurology and Psychiatry, Kodaira-shi, Japan
🇯🇵St.Marianna University Hospital, Kawasaki-shi, Japan
🇯🇵Chiba University Hospital, Chiba-shi, Japan
TOPIK Study: A Study to Report Progressive Multifocal Leukoencephalopathy and Other Serious Opportunistic Infections in Natalizumab Treated Participants
- First Posted Date
- 2022-02-11
- Last Posted Date
- 2024-07-17
- Lead Sponsor
- Biogen
- Target Recruit Count
- 600
- Registration Number
- NCT05236777
- Locations
- 🇨🇿
Všeobecná fakultní nemocnice v Praze, Prague, Czechia
🇨🇿Nemocnice Teplice, Teplice, Czechia
🇨🇿Fakultní nemocnice Brno, Brno, Czechia
Analysis of MS Patients Who Have Had Greater Than 60 Infusions of Natalizumab
- Conditions
- First Posted Date
- 2021-07-16
- Last Posted Date
- 2022-03-24
- Target Recruit Count
- 42
- Registration Number
- NCT04964700
- Locations
- 🇺🇸
Multiple Sclerosis Center of Northeastern New York, P.C., Latham, New York, United States
Study of Tysabri in Early Relapsing Remitting Multiple Sclerosis Participants
- First Posted Date
- 2021-04-05
- Last Posted Date
- 2024-02-05
- Lead Sponsor
- Biogen
- Target Recruit Count
- 60
- Registration Number
- NCT04832399
- Locations
- 🇵🇹
Research Site, Vila Nova de Gaia, Portugal
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.